Study wrapper · #523
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease.
Editor's note
This is a mechanistic immune-marker analysis nested in a 12-month randomized, double-blind, placebo-controlled trial (61 participants with HIV and NAFLD) of tesamorelin, using proteomics plus gene-set enrichment on liver biopsies. Researchers reported that tesamorelin, versus placebo, was associated with significant decreases in 13 circulating proteins related to T-cell and monocyte/macrophage activation (with none increasing), and that liver tissue showed a matching down-regulation of immune-activation pathways. This is a well-designed mechanistic readout suggesting that augmenting the growth-hormone axis may dampen immune activation in a metabolically dysregulated HIV population. The sample is small and the endpoints are biomarkers rather than clinical outcomes, so read it as supportive mechanistic evidence, not proof of clinical immune benefit.
Plain-language abstract
This study asked whether tesamorelin, which boosts the body's own pulses of growth hormone, also affects the immune system. Using blood samples and liver biopsies from a 12-month randomized, double-blind, placebo-controlled trial in 61 people with HIV and fatty liver disease, researchers measured 92 immune-related proteins. Compared with placebo, tesamorelin was associated with lower levels of 13 proteins linked to the activity of certain immune cells (T-cells and monocytes/macrophages), and none went up. Analysis of the liver tissue showed the same quieting of immune-activation pathways. The authors suggest that raising growth-hormone activity may calm immune activation in people with HIV who have metabolic problems. Because the study measured immune markers in a small group rather than health outcomes, it points to a possible mechanism rather than proving a clinical benefit.